Some rebrandings are little more than a new logo. Others come at a point when an organisation needs to give a clear identity to something that has become significantly larger, broader and more complex.
That is the case with ProductLife Group, which on 29 September unveiled its new identity, PLG | Advanced Intelligence for Life Sciences, as the expression of an integration journey involving 26 companies acquired over the past six years. On the occasion of the launch, we interviewed James Burt, CEO of PLG, to explore what it means to turn acquisition-led growth into a genuinely integrated model, and what role intelligent automation and senior expertise can play in that process. Full integration of the Group is expected to be completed by the end of 2027.
The numbers already tell part of the story. Twenty-six acquisitions in six years mean bringing together different capabilities, corporate cultures, service portfolios, markets and operating models, and making them function as one system. This is where PLG’s announcement becomes relevant beyond the boundaries of the company itself.
From a collection of capabilities to true integration
PLG’s new structure is organised around four Business Units.
Product Development & Engineering covers the journey from molecule to manufacturing, bringing together preclinical and clinical development, CMC, regulatory and engineering expertise. Market & Patient Access includes market access, HTA, pricing, health economics and patient-centred evidence. Product Compliance covers regulatory affairs, safety and vigilance, and quality assurance. Digital & Innovation, finally, focuses on digital transformation and AI-enabled solutions connecting functions from R&D and quality to manufacturing and commercial operations.
The structure matters, but perhaps even more important is the logic behind it.
PLG points out that most projects draw on expertise from more than one Business Unit. The aim is therefore to provide clients with a single partner capable of building a cross-functional response, rather than requiring them to coordinate several specialist providers.
This is a familiar challenge in Life Sciences. Development, manufacturing, quality, regulatory, market access and digitalisation can all be represented as distinct phases or functions on a diagram. In practice, however, decisions taken in one area almost always have consequences in others.
A process change may have regulatory implications. A development strategy can shape future manufacturing choices. The evidence model selected during development may affect access. The introduction of digital tools touches technology, quality, compliance and organisation at the same time.
The value of an integrated model therefore depends less on the number of capabilities available than on the ability to make them work together on the same problem.
Human + Artificial
A second element sits at the heart of PLG’s new identity: the relationship between professional expertise and automation.
The Group uses the expression Advanced Intelligence to describe a model that combines specialist expertise with intelligent automation, while keeping responsibility for every recommendation with senior Life Sciences professionals. Technology, in this model, is intended to accelerate and enhance their work without replacing their accountability.
This was also one of the central themes addressed by James Burt in the video interview recorded for the launch of the new brand: what happens when artificial intelligence enters highly specialised and regulated activities? And where does automation stop, while human judgement remains essential?
PLG’s answer is encapsulated in the formula Human + Artificial.
Burt summarised the concept in the statement accompanying the launch: “Professional expertise and intelligent automation working together, with a senior expert accountable for every decision.” He added: “It is this combination of human and artificial intelligence that should define a complete partner for the Life Sciences sector today.”
These two statements shift the discussion around AI from a purely technological question to an organisational one.
In a regulated sector, the issue is not simply how much of an activity can be automated. Supervision, traceability, the quality of the information used, validation of outputs and, above all, accountability are just as important.
Automation can reduce repetitive work, accelerate analysis and help manage volumes of information that would be difficult to handle manually. But when those insights need to support decisions concerning the development, quality, safety or compliance of a medicinal product, knowing who remains accountable is essential.
This is perhaps the most concrete meaning behind the formula chosen by PLG.
A CEO joining during the transformation
James Burt joined ProductLife Group in 2026, bringing more than twenty years of international experience across the pharmaceutical value chain, including previous roles at Pharmanovia and Accord Healthcare.
His perspective in the interview is therefore a particular one: that of someone who joined the organisation after much of its acquisition-led expansion had already taken place, and who is now leading the next phase.
As Burt put it: “When I joined PLG at the beginning of this year, I found an organisation that had already achieved something rare in our sector: one Group with a genuinely complete range of capabilities across the entire Life Sciences product lifecycle.”
That is precisely the point. Having all the capabilities required across the lifecycle does not automatically mean that an end-to-end model has already been built.
The real challenge comes afterwards: connecting those capabilities closely enough to ensure that the organisation no longer behaves like the sum of the companies from which it originated.
Global scale
The launch of the new brand also comes at a time when PLG has reached significant international scale. The Group reports more than 2,000 clients, around 2,000 professionals from 60 nationalities, a direct presence in more than 50 countries and coverage of over 150 countries through its partner network.
These figures also help explain why integration is more than an organisational detail.
As scale increases, so does the risk that a wealth of expertise may generate fragmentation: more specialisations, more structures, more systems and more handovers between teams. Technology can help reduce some of this complexity, but only when it is embedded in clearly defined processes and responsibilities.
This is where PLG’s rebranding takes on a meaning that goes well beyond visual identity.
The new logo, according to the company, represents different forces converging in the same direction. But the real test will happen elsewhere: in projects where regulatory, engineering, quality, access and digital must stop being separate capabilities available within the same Group and become a single way of addressing the client’s problem.
Ultimately, this is the question raised by PLG’s transformation. In an industry where specialisation and complexity are both increasing, will competitive advantage continue to come from possessing individual capabilities, or increasingly from the ability to connect them?
The answer will take time. PLG itself identifies the end of 2027 as the horizon for completing the integration. For now, the new brand makes the direction clear.
Vuoi trovare più facilmente MakingPharmaIndustry su Google?
Aggiungici alle tue fonti preferite
